Johnson & Johnson to Acquire Halda Therapeutics in $3.05B
Johnson Johnson Halda Therapeutics is a key focus in Johnson & Johnson's strategy to expand its oncology portfolio through a $3.05 billion acquisition.
Most important news & global events daily
Johnson Johnson Halda Therapeutics is a key focus in Johnson & Johnson's strategy to expand its oncology portfolio through a $3.05 billion acquisition.
Your cart is currently empty!
Notifications